Lindsay Stewart, PA
Physician Assistant · Butler, PANPI 1205061967
Payments from drug & device makers
Across 260 payments — averaging $25.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cequr Corporation$2K
- Novo Nordisk$2K
- Lilly USA, LLC$795
- AstraZeneca$376
- Medtronic$243
- Sanofi-aventis U.S. LLC$227
- plus $2K from 25 others
What the payments were for
- Food & beverage$6,641100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cequr Corporation | 4 | $1,681 |
| Novo Nordisk | 82 | $1,582 |
| Lilly USA, LLC | 49 | $795 |
| AstraZeneca(2 entities) | 9 | $376 |
| Medtronic | 5 | $243 |
| Sanofi-aventis U.S. LLC | 13 | $227 |
| Amgen | 10 | $177 |
| BD | 8 | $166 |
| Bayer | 10 | $166 |
| AbbVie | 9 | $159 |
| Dexcom, Inc. | 9 | $135 |
| IBSA Pharma Inc. | 5 | $100 |
| Abbott | 6 | $93 |
| Amneal Pharmaceuticals LLC | 5 | $90 |
| Ascendis Pharma Endocrinology Inc | 4 | $70 |
| Antares Pharma, Inc. | 4 | $63 |
| Insulet Corporation | 3 | $58 |
| Xeris Pharmaceuticals, Inc. | 3 | $55 |
| Tandem Diabetes Care, Inc. | 3 | $51 |
| Madrigal Pharmaceuticals | 2 | $48 |
| Embecta Corp. | 2 | $42 |
| BETA Bionics, Inc. | 2 | $41 |
| Neurocrine Biosciences, Inc. | 2 | $38 |
| Amphastar Pharmaceuticals, Inc. | 2 | $33 |
| Kyowa Kirin, Inc. | 2 | $32 |
| Boehringer Ingelheim | 2 | $28 |
| Soleno Therapeutics, Inc. | 1 | $20 |
| Radius Health, Inc. | 1 | $19 |
| Currax Pharmaceuticals LLC | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Alvogen Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CeQur Simplicity$1,607
- FARXIGA$239
- INPEN SMART INSULIN DELIVERY SYSTEM$156
- Wegovy$124
- Ozempic$103
How this compares
$6,641 in reported general payments places this provider in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 306 | $391,003 |
| TrulicityDulaglutide | 335 | $388,031 |
| JardianceEmpagliflozin | 206 | $211,914 |
| MounjaroTirzepatide | 112 | $128,796 |
| Tresiba Flextouch U-100Insulin Degludec | 87 | $59,425 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 33 | $53,818 |
| Tresiba Flextouch U-200Insulin Degludec | 44 | $48,142 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 72 | $41,441 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 275 | $36,791 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $36,075 |
| Humalog Kwikpen U-100Insulin Lispro | 118 | $32,184 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 23 | $27,541 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 61 | $26,925 |
| RybelsusSemaglutide | 24 | $22,776 |
| Humalog Kwikpen U-200Insulin Lispro | 18 | $22,030 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $795 | $521,637464 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $1,582 | $419,406345 claims |
| Boehringer IngelheimJardiance | $28 | $211,914206 claims |
| AstraZenecaFarxiga | $376 | $21,61022 claims |
| AbbVieSynthroid | $159 | $8,145122 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $90 | $3,488281 claims |
| Sanofi-aventis U.S. LLCLantus | $227 | $2,91318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.
Other physician assistant in Butler
- Erin CrownState College$1.5M
- Tricia BootsCranberry Twp$313K
- Melissa FerrariPhiladelphia$223K
- Jason OberdickWexford$206K
- Justine RobertsMurrysville$173K
- Allison BoydErie$163K
- Joshua TrbovichWashington$144K
- Daniel TelegaErie$124K
- Alvin KingcadePhiladelphia$101K
- Jeffrey CameronWashington$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.